⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28282335 | 0.91 | — | — | |
| SCHEMBL13199855 | 0.84 | CXCR4 (0.35) | — | |
| SCHEMBL1102255 | 0.84 | — | — | |
| SCHEMBL18161889 | 0.82 | CXCR4 (0.40) | — | |
| Hydrochloric Acid SCHEMBL10515769 | 0.82 | — | — | |
| SCHEMBL22485390 | 0.81 | — | — | |
| SCHEMBL19593830 | 0.80 | ALDH1A1 (0.38) | — | |
| SCHEMBL63693 | 0.80 | CXCR4 (0.35) | — | |
| SCHEMBL2907938 | 0.80 | CXCR4 (0.35) | — | |
| SCHEMBL24606523 | 0.78 | CXCR4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| WO-2023215801-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023114428-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022197755-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022159421-A1 | IONIZABLE LIPIDS FOR NANOMATERIALS | BEAM THERAPEUTICS INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-11014902-B2 | MYC G-quadruplex stabilizing small molecules and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3798214-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2021-03-31 | — | — | EP | disclosed |
| WO-2021027943-A1 | PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2020227132-A1 | COMPOUNDS FOR TREATING CANCER | Terns, Inc. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20070129356-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070082906-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-04-12 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070060601-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-15 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| US-20040198926-A1 | Novel phenolic resins | ANGUS CHEMICAL COMPANY | 2004-10-07 | — | — | US | disclosed |
| WO-2004015039-A1 | NITROGEN COMPOUNDS FOR GAS ODORISATION | SYMRISE GMBH & CO. KG (DE) | 2004-02-19 | — | — | WO | disclosed |
| US-5010196-A | Acylated hexahydropyrimidines | JOHN WYETH AND BROTHERS LIMITED (GB) | 1991-04-23 | — | — | US | disclosed |
| EP-0405932-A2 | Substituted 1,3-Diaminopropanes | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-02 | — | — | EP | disclosed |